Annual reportAug 2026
Aug 2026 · Shareholders meeting 31 Jul - Integrated Annual Report FY2025-26 and AGM notice for August 25, 2026; director reappointments proposed.
Source: Nse
JFL Life Sciences Ltd. (JFLLIFE)
SME CapPharma stocks · SME cap · NSE
JFL Life Sciences Ltd. operates in Formulations, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 19 Oct, 03:31 pm ISTDetails
Quote19 Oct, 03:31 pm IST
Base fundamentals20 Oct 2026 · screener
Latest result16 Aug, 12:44 am IST
Score20 Oct, 04:19 pm IST · v4.3-runtime-valuation
Tags24 Apr 2026
Coverage13/14 · 93%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
62BullishSMA20 -11.1% / mo · MACD + · sector +3.8pp vs Nifty 500 (3M)
Stock trend: 38
Sector RS: 98
Sector 3M: -1.8% vs Nifty 500 -5.6%
Pharma FPI tailwindFlow only
FPI equity flow was positive in both fortnights, but the sector index is below its 100-session average. View sector evidence
Technical chart
JFLLIFED candles · FIT view+10.7%Latest close ₹10.35 on 2026-10-19
Bar
+0.0%
RSI
47
MACD hist
0.12
52W pos
26%
2026-10-19O ₹10.35H ₹10.35L ₹10.35C ₹10.35Vol 6,000 sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
JFLLIFENifty PharmaNifty 500
- JFLLIFE
- -5.9%
- Nifty 500
- -5.6%
- Nifty Pharma
- -1.5%
- Vs Nifty 500
- -0.3 pp
Chart stats
19 Oct 2026- From 52W high
- -39.5%
- 52W range position
- 21%
- ATR (14)
- 3.9%
- Volume vs 20D
- 0.29x
- Avg traded value
- ₹0 Cr
- 20D price channel
- ₹9.7 - ₹11.4
₹17.1
₹8.6 - ₹17.1
₹0.4
Latest completed session
20-session average
54.2% annualized volatility
Research snapshot
What the evidence says now
Investable fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend is neutral, and recent execution is mixed.
Suggested next step
Research, do not rush
The evidence is not strongly aligned. Compare peers and wait for a cleaner setup.
U-Score
Legacy · UNDERVALUED69
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Average40
Revenue -4.2% · PAT +48.0% YoY
Technical
Bullish62
Price trend and sector-relative-strength timing.
Valuation
Legacy model+88.8%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence69
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Average · 40/100Rev -4% YoY · PAT +48% YoY · margin expansion · operating leverage
Filed 30 Jun 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹11.1 Cr | -4.2% | -82.4% |
| EBITDA | ₹2.1 Cr | +8.3% | -40.5% |
| Operating margin | 18.8% | +218 bps | +1326 bps |
| PAT | ₹1.1 Cr | +48.0% | -33.1% |
| PAT margin | 10.0% | +353 bps | +737 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 5.05
- P/B
- 0.75
- EV/EBITDA
- 4.32
- Market Cap
- 34.20Cr
Profitability
- ROE
- 15.00%
- ROCE
- 18.20%
- ROA
- 6.60%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- 32.00%
- EPS 5Y
- 64.00%
- Revenue 3Y
- 45.00%
- EPS 3Y
- 32.00%
Balance Sheet
- Debt/Equity
- 0.48
- Interest Coverage
- 6.00×
- Altman Z
- 2.28
- Book Value
- 13.90
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 2/5
- OCF
- -4.00 Cr
- EPS TTM
- 2.05
Shareholding
- Promoter Hold
- 67.47%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 27%
Financial History
Updated 19/10/2026
Revenue
₹ CrLatest: 131+59.8% vs prev
Net Profit
₹ CrLatest: 6.0+50.0% vs prev
Return on Equity
%Latest: 13.0+27.1% vs prev
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
NeutralTrend is undirectional — long-term trend unclear. RSI 47.
- SMA20 falling (~12.5% over last month) — short-term momentum negative.
- RSI(14) at 47 — sideways, no extreme reading.
- MACD above signal but histogram contracting — bullish momentum cooling.
- 33% off 52W high · 21% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Valuation & peers
U-Score 69 · legacy U-Score band UNDERVALUED · valuation evidence and comparable companies
Valuation & peers
U-Score 69 · legacy U-Score band UNDERVALUED · valuation evidence and comparable companies
Deep Value
Fundamental score breakdown
U band · UNDERVALUEDValuation30/30
Growth21/25
Quality13/20
Balance Sheet9/15
Cash Flow1/10
Piotroski
6/9 (+3)
Penalties
-8
Raw sum
69
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
69/100 · legacy band UNDERVALUED
Positive drivers
- Fair-value margin of safety is positive at 88.8%.
- Valuation contributes 30/30 to the score.
- Growth contributes 21/25 to the score.
Main drags
- Penalty bucket subtracts 8 points.
- Cash flow is weaker at 1/10; verify the latest quarterly trend.
- Balance sheet is weaker at 9/15; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
5.0
PB
0.8
EV/EBITDA
4.3
ROE
15.0%
ROCE
18.2%
FCF Yield
—
Debt/Equity
0.5
MoS
+88.8%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 20 Oct 2026
v4.3-runtime-valuation
Final score
69
Previous: 69
Legacy U-Score band
UNDERVALUED
Previous: UNDERVALUED
Margin of safety
+88.8%
Previous: +88.8%
Score history
12 stored score snapshots. Latest stored move: +4 points.
20 Oct 2026
v4.3-runtime-valuation
65
65
65
65
65
65
65
65
65
65
65
69
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹25.32
+59.1% MoS
Growth-justified P/E
45.0
Growth-justified Value
₹92.25
+88.8% MoS
PEG
0.10
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
SUNREST
SME
Sunrest Lifescience Ltd.
Pharmaceuticals
match 162
68
5.5
15.2%
+91%
UNDERVALUED
ARISTO
SME
Aristo Bio-Tech and Lifescience Ltd.
Pharmaceuticals
match 160
77
8.5
17.6%
+81%
DEEP VALUE
MONOPHARMA
SME
Mono Pharmacare Ltd.
Pharmaceuticals
match 158
18
21.6
2.3%
-408%
OVERVALUED
ZENITHDRUG
SME
Zenith Drugs Ltd.
Pharmaceuticals
match 156
75
6.9
26.3%
+84%
DEEP VALUE
ONYX
SME
Onyx Biotec Ltd.
Pharmaceuticals
match 154
15
—
-0.4%
—
OVERVALUED
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
JFL Life Sciences Ltd. operates in Formulations, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
69Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 59th percentile of the scored universe and 46th percentile within Pharma. Main check: cash conversion is weak at 40/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
0 docs text-extracted · 0 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
59th percentile
overall median 67 · Pharma: 46th pctile, median 70 · SME: 77th pctile, median 64
Evidence depth
Financial-only
0 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Acceptable, but check the weakest sub-score before increasing exposure.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
86
strong · holding, pledge, alignment
Cash flow
40
weak · profit to cash conversion
Balance sheet
81
strong · leverage and solvency
Discipline
76
strong · capital discipline
Results
70
acceptable · quarterly consistency
Trust positives
- ▸Promoter holding is 67.5%.
- ▸Promoter pledge is zero.
- ▸4/4 latest quarters had positive YoY PAT growth.
- ▸Latest 3 quarters had positive YoY PAT growth.
Trust risks
- ▸Operating cash flow is negative at ₹-4 Cr.
- ▸2 older quarters in the 8-quarter window had PAT decline worse than 25% YoY.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching JFL Life Sciences Ltd.
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Annual reportMar 2026
Mar 2026 · Annual Report 2026
Source: Nse
Annual reportMar 2025
Mar 2025 · Annual Report 2025
Source: Nse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.